This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.
Our work during 2022 spanned from assisting start-up companies expanding abroad for the first time to advising large multinationals on multibillion-dollar...
In this issue of Insights: Transfer Pricing, we include recent articles on transfer pricing issues, an upcoming speaking engagement, and industry...
CRA is a proud sponsor of the event. Rebel Curd is a panelist during the session titled “Analyzing transfer pricing cases and controversy strategies.” Anna...
Blockchain-based projects can incorporate multiple jurisdictions and require complex governance design, with operational and tax implications. This webinar...
